EAM Investors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

EAM Investors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.57M	Sell	55,765 -729	-1%	-$37.8K	0.32%	146
2026 Q1	$2.72M	Sell	56,494 -39,524	-41%	-$1.75M	0.31%	147
2025 Q4	$3.96M	Sell	96,018 -1,921	-2%	-$77.1K	0.44%	118
2025 Q3	$3.74M	Sell	97,939 -7,808	-7%	-$254K	0.43%	116
2025 Q2	$2.93M	Buy	+105,747	New	+$2.69M	0.44%	111
2023 Q4	–	Sell	-124,438	Closed	-$2.16M	–	317
2023 Q3	$2.16M	Buy	+124,438	New	+$2.1M	0.42%	87
2023 Q1	–	Sell	-79,046	Closed	-$1.18M	–	317
2022 Q4	$1.18M	Buy	+79,046	New	+$1.15M	0.25%	191

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

EAM Investors's KNSA Position: Q2 2026 in Review

EAM Investors reduced its Kiniksa Pharmaceuticals (KNSA) stake by 1.3% in Q2 2026, selling an estimated $37.8K and leaving 55,765 shares worth $3.57M. The position accounts for 0.32% of the portfolio, ranked #146.

EAM Investors first reported a position in KNSA in Q4 2022 and has held it in 7 quarters since. The position peaked at $3.96M in Q4 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

EAM Investors held 55,765 shares of Kiniksa Pharmaceuticals worth $3.57M as of Q2 2026.
EAM Investors sold 729 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $37.8K.
Kiniksa Pharmaceuticals made up 0.32% of EAM Investors's portfolio in Q2 2026, its #146 holding.
EAM Investors first reported a position in Kiniksa Pharmaceuticals in Q4 2022 and has held it in 7 quarters since.
EAM Investors's Kiniksa Pharmaceuticals position peaked at $3.96M in Q4 2025.
266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.